Edward J Fox

Summary

Publications

  1. ncbi request reprint Mechanism of action of mitoxantrone
    Edward J Fox
    MS Clinic of Central Texas, 7200 Wyoming Springs Dr, Suite 1100, Round Rock, TX 78681, USA
    Neurology 63:S15-8. 2004
  2. ncbi request reprint Immunopathology of multiple sclerosis
    Edward J Fox
    Multiple Sclerosis Clinic of Central Texas, 7200 Wyoming Springs Dr, Suite 1100, Round Rock, TX 78681, USA
    Neurology 63:S3-7. 2004
  3. ncbi request reprint The immunogenicity of disease-modifying therapies for multiple sclerosis: clinical implications for neurologists
    Edward J Fox
    University of Texas Medical Branch, MS Clinic of Central Texas, Round Rock, Texas 78681, USA
    Neurologist 13:355-62. 2007
  4. ncbi request reprint Management of worsening multiple sclerosis with mitoxantrone: a review
    Edward J Fox
    Multiple Sclerosis Clinic of Central Texas, Round Rock 78681, USA
    Clin Ther 28:461-74. 2006
  5. ncbi request reprint Emerging oral agents for multiple sclerosis
    Edward J Fox
    Central Texas Neurology Consultants, 16040 Park Valley Dr, Bldg B, Ste 100, Round Rock, TX 78681, USA
    Am J Manag Care 16:S219-26. 2010
  6. doi request reprint New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis
    Edward J Fox
    Multiple Sclerosis Clinic of Central Texas, University of Texas Medical Branch, Round Rock, Texas 78681, USA
    Curr Opin Neurol 25:S11-9. 2012
  7. doi request reprint Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis
    Edward J Fox
    University of Texas Medical Branch, MS Clinic of Central Texas, 16040 Park Valley Drive, Round Rock, TX 78681, USA
    Expert Rev Neurother 10:1789-97. 2010
  8. ncbi request reprint Mitoxantrone for multiple sclerosis in clinical practice
    Syed A Rizvi
    Department of Clinical Neurosciences, Brown University, 2 Dudley Street, Suite 555, Providence, Rhode Island 02905, USA
    Neurology 63:S25-7. 2004

Detail Information

Publications8

  1. ncbi request reprint Mechanism of action of mitoxantrone
    Edward J Fox
    MS Clinic of Central Texas, 7200 Wyoming Springs Dr, Suite 1100, Round Rock, TX 78681, USA
    Neurology 63:S15-8. 2004
    ..Finally, it inhibits macrophage-mediated myelin degradation. Compared with interferon betas, mitoxantrone has a broad range of actions and has effects on many different types of immune cells...
  2. ncbi request reprint Immunopathology of multiple sclerosis
    Edward J Fox
    Multiple Sclerosis Clinic of Central Texas, 7200 Wyoming Springs Dr, Suite 1100, Round Rock, TX 78681, USA
    Neurology 63:S3-7. 2004
    ..Because axon loss is irreversible and is responsible for long-term disability, therapies are also needed that enhance remyelination or are neuroprotective...
  3. ncbi request reprint The immunogenicity of disease-modifying therapies for multiple sclerosis: clinical implications for neurologists
    Edward J Fox
    University of Texas Medical Branch, MS Clinic of Central Texas, Round Rock, Texas 78681, USA
    Neurologist 13:355-62. 2007
    ..Therefore, it is important to understand the causes of immunogenicity, methods for assessing antibody status, and the clinical impact of NAbs, particularly in patients who appear to be nonresponsive to treatment...
  4. ncbi request reprint Management of worsening multiple sclerosis with mitoxantrone: a review
    Edward J Fox
    Multiple Sclerosis Clinic of Central Texas, Round Rock 78681, USA
    Clin Ther 28:461-74. 2006
    ....
  5. ncbi request reprint Emerging oral agents for multiple sclerosis
    Edward J Fox
    Central Texas Neurology Consultants, 16040 Park Valley Dr, Bldg B, Ste 100, Round Rock, TX 78681, USA
    Am J Manag Care 16:S219-26. 2010
    ....
  6. doi request reprint New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis
    Edward J Fox
    Multiple Sclerosis Clinic of Central Texas, University of Texas Medical Branch, Round Rock, Texas 78681, USA
    Curr Opin Neurol 25:S11-9. 2012
    ..The aims of this article are to review emerging therapies for multiple sclerosis (MS) and to consider new approaches to assessment and achievement of treatment success in patients with this disease...
  7. doi request reprint Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis
    Edward J Fox
    University of Texas Medical Branch, MS Clinic of Central Texas, 16040 Park Valley Drive, Round Rock, TX 78681, USA
    Expert Rev Neurother 10:1789-97. 2010
    ..Enrollment in two pivotal Phase III clinical trials of alemtuzumab in MS is now complete...
  8. ncbi request reprint Mitoxantrone for multiple sclerosis in clinical practice
    Syed A Rizvi
    Department of Clinical Neurosciences, Brown University, 2 Dudley Street, Suite 555, Providence, Rhode Island 02905, USA
    Neurology 63:S25-7. 2004
    ..g., reduction in disease progression) outweigh the risks for patients with aggressive or worsening disease. With the selection of appropriate patients and careful monitoring for adverse events, mitoxantrone can be safely administered...